BRCA2 and neoplasm: Therefore, these approaches can successfully be implemented in a diagnostic setting to screen for germline defects in BRCA1 and BRCA2 using blood‐derived DNA [D'Argenio et al., 2015; Trujillano et al., 2015], but cannot be used to sequence low quality and highly fragmented DNA derived from FFPE tumor blocks.